MiMedx Group Inc MDXG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
-
MiMedx Eliminates COO Role Amid Cost-Savings Push
Trading Information
- Previous Close Price
- $3.68
- Day Range
- $3.63–3.73
- 52-Week Range
- $3.03–7.99
- Bid/Ask
- $3.69 / $3.84
- Shares Outstanding
- 148.95M
- Market Cap
- $551.10M
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 10.77
- Price/Sales
- 1.38
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.48%
Company Profile
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 808
- Website
- https://www.mimedx.com
Valuation
|
Metric
|
MDXG
|
|---|---|
Price/Earnings (Normalized) | 10.77 |
Price/Book Value | 2.21 |
Price/Sales | 1.38 |
Price/Cash Flow | 8.02 |
Price/Earnings
MDXG
Financial Strength
|
Metric
|
MDXG
|
|---|---|
Quick Ratio | 4.62 |
Current Ratio | 5.39 |
Interest Coverage | — |
Quick Ratio
MDXG
Profitability
|
Metric
|
MDXG
|
|---|---|
Return on Assets (Normalized) | 16.39% |
Return on Equity (Normalized) | 21.68% |
Return on Invested Capital (Normalized) | 19.14% |
Return on Assets
MDXG
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Cxmhfhfs | Vzrbyrh | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Srhvwnww | Qrbgl | $64B | |||
| argenx SE ADR
ARGX
| Lhvgdwpf | Yqcln | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kspgnfd | Jmswwpg | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Qyvnwkfj | Wzjzn | $24B | |||
| BioNTech SE ADR
BNTX
| Mqmbvxl | Bwg | $23B | |||
| Incyte Corp
INCY
| Jkljcvbz | Yvtdp | $22B | |||
| Moderna Inc
MRNA
| Dzcjfwpz | Pkjlw | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Wqtzhljtr | Vqdsh | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Yqtwtyg | Cgkv | $13B |
United States